Abstract: Sweet's syndrome is a rare dermatosis with little-known pathogenesis, associated with some clinical conditions such as infections, autoimmune diseases, inflammatory bowel diseases, vaccination, medications and neoplasms. Hematologic malignancies are the diseases most related to paraneoplastic Sweet's syndrome, but this clinical entity can also be found occasionally in some solid tumors, including genitourinary tract tumors. We report a rare case of paraneoplastic Sweet's syndrome associated with the diagnosis of cervical cancer.
INTRODUCTION
Paraneoplastic syndromes are clinical conditions that are related to primary or metastatic tumors but are not directly attributed to the physical effects of these neoplasias. They can occur concomitantly or precede the oncological condition, and the treatment of the neoplasia generally leads to their resolution.
Sweet's syndrome was first described by Robert Douglas Sweet in 1964. It is a rare, etiologically unknown dermatosis that can be idiopathic or associated with certain clinical conditions. 1 Among these conditions are infections, autoimmune diseases, inflammatory bowel diseases, vaccinations, the use of medications, and neoplasias. Hematological neoplasias, particularly acute myeloid leukemia, are the most commonly described, but the condition may also be related to solid tumors, being those of the genitourinary tract the most associated with the syndrome. Sweet's syndrome generally responds well to treatment with corticosteroids, independent of the hidden malignant neoplasm, and treatment of the neoplasia results in complete remission of the syndrome. 4 In the present report of the clinical and histopathological diagnosis of Sweet's syndrome, we considered it to be of paraneoplastic etiology, based on the laboratory tests and on the fact that the patient is known to have cervical neoplasia. Paraneoplastic Sweet's syndrome was then diagnosed, and treatment of this pathology was initiated. Currently in the literature, only four cases relate Sweet's syndrome to cervical cancer. 5, 6 The preferred treatment for neoplasia associated with
CASE REPORT
Sweet's syndrome is that in progress and may result in complete remission of the syndrome in the case of a solid tumor. However, a cycle of systemic corticosteroid is administered preliminarily. Systemic corticosteroids are the reference standard in the treatment of classic Sweet's syndrome, and prednisone is the most commonly used drug. 7 Nevertheless, there is no specific guideline for the treatment of Sweet's syndrome related to malignant neoplasias. Conception and planning of the study; Elaboration and writing of the manuscript; Obtaining, analyzing and interpreting the data; Intellectual participation in propaedeutic and/or therapeutic conduct of the cases studied
